Skip to main content
Antoni Ribas, MD, Hematology, Los Angeles, CA

AntoniRibasMD

Hematology Los Angeles, CA

Professor, Medicine, UCLA School of Medicine

Dr. Ribas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Ribas' full profile

Already have an account?

  • Office

    100 Med Plz
    Ste 550
    Los Angeles, CA 90095

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
  • Universidad de Barcelona Faculty of Medicine
    Universidad de Barcelona Faculty of MedicineClass of 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2001 - 2025

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2009

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Isolation and Characterization of NY-ESO-1–Specific T Cell Receptors Restricted on Various MHC Molecules  
    Antoni Ribas, Proceedings of the National Academy of Sciences
  • Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based Immunotherapy  
    Jonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
  • Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers  
    Antoni Ribas, Jennifer A Wargo, Sumit K Subudhi, Padmanee Sharma, Clinical Cancer Research
  • Join now to see all

Lectures

  • Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-Treated Patients with BRAFV600-Mutated Metastatic Melanoma 
    International Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/24/2012
  • International Society for Biological Therapy of Cancer (iSBTc): Annual Meeting 
    International Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/26/2012

Authored Content

  • Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients with Advanced Melanoma Treated with Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical TrialAugust 2018

Press Mentions

  • UCLA and Parker Institute Continue Collaboration to Advance Next-Generation Cancer Immunotherapies
    UCLA and Parker Institute Continue Collaboration to Advance Next-Generation Cancer ImmunotherapiesOctober 16th, 2024
  • Cancer Spread to Jimmy Carter's Brain 9 Years Ago. Here's How He's Lived so Long
    Cancer Spread to Jimmy Carter's Brain 9 Years Ago. Here's How He's Lived so LongSeptember 30th, 2024
  • Cancer Treatment Extended Jimmy Carter’s Life Before His 100th Birthday
    Cancer Treatment Extended Jimmy Carter’s Life Before His 100th BirthdaySeptember 30th, 2024
  • Join now to see all

Other Languages

  • Spanish